News Conference News TCT 2022 FAVOR III China: Early Gains of QFR in PCI Persist to 2 Years L.A. McKeown September 20, 2022
News Daily News AI-Enabled Algorithm Succeeds in Identifying Diabetes From ECG Data Yael L. Maxwell August 12, 2022
News Daily News Few Adults Eligible for Primary Prevention With Statins in Latest ESC Guidelines Michael O'Riordan July 06, 2022
News Daily News Grieving a Loved One Increases Mortality Risk in HF Patients L.A. McKeown July 06, 2022
News Daily News Impact of Lower BP Cutoffs to Define Hypertension Varies Globally Todd Neale May 24, 2022
News Daily News Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV Michael O'Riordan May 09, 2022
News Conference News HRS 2022 EP’s Diversity Problem: Women, Minorities Remain Underrepresented Todd Neale May 06, 2022
News Daily News Don’t Rule Out CABG for Elderly Patients With Multiple Comorbidities Michael O'Riordan April 25, 2022
News Daily News Making a Game of Digital Tools Ups Exercise in High-Risk Postpartum Women Caitlin E. Cox April 25, 2022
News Daily News Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention Michael O'Riordan March 30, 2022
News Daily News Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia L.A. McKeown March 22, 2022
News Daily News Poor Prepregnancy Cardiometabolic Health Observed Across the US Yael L. Maxwell February 14, 2022
News Daily News Absence of CAC May be Protective Even in Patients With Very High Cholesterol Michael O'Riordan February 14, 2022
News Conference News THT 2022 Probe Beyond Ejection Fraction to Understand and Manage HFpEF L.A. McKeown February 07, 2022
News Daily News Using Donor Hearts After Circulatory Death Is Feasible for Transplantation Michael O'Riordan January 12, 2022
News Daily News Stimulants Linked to Early Risk of CV Events in Elderly Michael O'Riordan October 25, 2021
News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ESC 2021 PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer Michael O'Riordan August 30, 2021